Sr. Manager, Corporate Strategy and New Product Planning

The Senior Manager, Corporate Strategy and New Product Planning will play a pivotal role in shaping the commercial direction of Lexeo’s leading cardiac programs and organization. With multiple catalysts expected in 2026, it is crucial to define and refine commercial assumptions as lead programs advance, and to support the expansion of Lexeo’s growing commercial organization and capabilities. This role focuses on characterizing the current and evolving landscape in gene therapy and rare cardiovascular disease, particularly Friedreich ataxia (FA) cardiomyopathy and arrhythmogenic cardiomyopathy (ACM). Additionally, this role will encompass corporate strategy responsibilities, supporting commercial development, pipeline strategy and prioritization and other high-impact projects with senior executives as Lexeo evolves.

Primary Responsibilities:
• Conduct market research, including primary and secondary research, to outline market dynamics in FA, ACM and across other genetic medicine targets, such as unmet needs, key stakeholders, existing treatment paradigms, and competition, focusing on the U.S. and key international markets.
• Leverage research and insights to define how the company’s gene therapy candidates may meet unmet needs and impact future treatment paradigms.
• Collaborate closely with clinical colleagues to understand target product profiles and identify patient populations eligible for treatment.
• Identify and map key stakeholders involved in the treatment of FA and ACM, as well as those involved in the potential administration of cardiac gene therapy.
• Compile information on current treatment costs, payer perspectives, patient coverage types, treatment expenditure, and other medical costs.
• Analyze commercially available gene therapies in key markets, identifying successful constructs that maximize patient access or enable value-based reimbursement.
• Outline recommended investments and timelines for commercial scale-up over the next three years, including necessary commercial capabilities and colleagues.
• Develop and implement operational plans to ensure the efficient execution of commercial and corporate strategies.
• Support senior executives and business development colleagues with corporate strategy initiatives such as pipeline prioritization and development strategy optimization and other organizational planning
• Monitor and evaluate the performance of commercial initiatives, providing insights and recommendations for continuous improvement.
• Advance Lexeo objectives commercially, including support for corporate communications, media awareness, and internal employee initiatives that increase knowledge and understanding of lead programs and strategies
• Work closely with colleagues in Clinical Development, Medical Affairs, Program Management, and other relevant departments to ensure cohesive strategy execution.
• Report to the Senior Director of Commercial Marketing, regularly updating on project progress and strategic recommendations.
• Present findings and strategic recommendations to company leadership, facilitating informed decision-making.

Required Skills & Qualifications :
• MBA with 7-10 years of professional experience in consulting, finance, marketing, sales, or biopharmaceuticals, with a focus on commercial strategy and operations.
• Experience in the healthcare and biopharmaceutical industry, with a deep understanding of global biopharmaceutical market trends.
• Proven ability to synthesize data from multiple sources and distill insights into clear, actionable business strategies.
• Strong project management skills with meticulous attention to detail and the ability to manage multiple priorities in a fast-paced environment.
• Excellent interpersonal communication skills and a track record of successful cross-functional collaboration.
• Ability to operate independently, driving projects to completion with minimal oversight.

About Lexeo

Lexeo Therapeutics is a clinical-stage genetic medicine company headquartered in New York City, pioneering cardiac genetic medicine candidates to treat the root causes of inherited cardiovascular diseases. Our lead program, LX2006, targets cardiomyopathy associated with Friedreich’s Ataxia and anchors a broader pipeline addressing genetically defined conditions such as hypertrophic and arrhythmogenic cardiomyopathies. Backed by a strong financial foundation, Lexeo is positioned to translate groundbreaking science into durable clinical impact.

Our work culture is a hybrid model with 2 days/week in the New York City office and 3 days working from home.

Lexeo Therapeutics is an EEO employer committed to an exciting, diverse, and enriching work environment.